Search results
Results from the WOW.Com Content Network
The DrugBank Online website is available to the public as a free-to-access resource. However, use and re-distribution of content from DrugBank Online or the underlying DrugBank Data, in whole or part, and for any purpose requires a license. Academic users can apply for a free license for certain use cases while all other users require a paid ...
Unlike other xanthines, doxofylline lacks any significant affinity for adenosine receptors and does not produce stimulant effects. This suggests that its antiasthmatic effects are mediated by another mechanism, perhaps its actions on phosphodiesterase. [1]
Dupilumab, sold under the brand name Dupixent, is a monoclonal antibody blocking interleukin 4 and interleukin 13, used for allergic diseases such as atopic dermatitis (eczema), asthma and nasal polyps which result in chronic sinusitis.
The most common side effects are reactions at the application site (including burning or stinging). [3] Crisaborole is a phosphodiesterase 4 (PDE-4) inhibitor, although its specific mechanism of action in atopic dermatitis is not known. [1] [2]
Zoliflodacin (development codes AZD0914 and ETX0914) is an experimental antibiotic that is being studied for the treatment of infection with Neisseria gonorrhoeae (). [1] It has a novel mechanism of action which involves inhibition of bacterial type II topoisomerases. [2]
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Pages for logged out editors learn more
Side effects may include burning at the site of application. [6] Allergic reactions may rarely occur. [6] Use is not recommended in the ear in people who have a hole in the eardrum. [7] It works against both bacterial and fungal causes of external ear infections. [7]
As of 17 April 2020, the application is still under review at the other agencies. [9] Tucatinib is a kinase inhibitor meaning it blocks a type of enzyme (kinase) and helps prevent the cancer cells from growing. [9] Tucatinib is approved for treatment after adults have taken one or more anti-HER2-based regimens in the metastatic setting. [9]